Johnson & Johnson (NYSE:JNJ) Shares Sold by NorthRock Partners LLC

NorthRock Partners LLC trimmed its position in shares of Johnson & Johnson (NYSE:JNJ) by 29.7% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 18,507 shares of the company’s stock after selling 7,815 shares during the quarter. NorthRock Partners LLC’s holdings in Johnson & Johnson were worth $2,928,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in JNJ. Christopher J. Hasenberg Inc acquired a new stake in shares of Johnson & Johnson in the first quarter valued at approximately $31,000. Keener Financial Planning LLC acquired a new stake in Johnson & Johnson during the fourth quarter worth approximately $40,000. WFA Asset Management Corp boosted its position in Johnson & Johnson by 61.4% during the fourth quarter. WFA Asset Management Corp now owns 255 shares of the company’s stock worth $40,000 after acquiring an additional 97 shares during the last quarter. Vermillion & White Wealth Management Group LLC acquired a new stake in Johnson & Johnson during the fourth quarter worth approximately $44,000. Finally, Disciplined Equity Management Inc. acquired a new stake in Johnson & Johnson during the fourth quarter worth approximately $45,000. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Johnson & Johnson Stock Up 1.1 %

Shares of JNJ traded up $1.63 during midday trading on Tuesday, hitting $150.87. The company had a trading volume of 513,355 shares, compared to its average volume of 7,220,401. The company’s 50 day moving average price is $147.95 and its 200 day moving average price is $153.41. The stock has a market cap of $363.10 billion, a price-to-earnings ratio of 9.30, a PEG ratio of 2.52 and a beta of 0.52. Johnson & Johnson has a 52 week low of $143.13 and a 52 week high of $175.97. The company has a quick ratio of 0.94, a current ratio of 1.17 and a debt-to-equity ratio of 0.36.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Tuesday, April 16th. The company reported $2.71 earnings per share for the quarter, topping the consensus estimate of $2.64 by $0.07. The company had revenue of $21.38 billion during the quarter, compared to the consensus estimate of $21.39 billion. Johnson & Johnson had a net margin of 45.26% and a return on equity of 36.70%. The company’s revenue was up 2.3% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.68 EPS. On average, equities research analysts predict that Johnson & Johnson will post 10.5 EPS for the current year.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on JNJ. The Goldman Sachs Group began coverage on shares of Johnson & Johnson in a research report on Thursday, May 30th. They set a “neutral” rating and a $160.00 target price on the stock. Bank of America decreased their price target on shares of Johnson & Johnson from $180.00 to $170.00 and set a “neutral” rating on the stock in a report on Wednesday, April 17th. Morgan Stanley decreased their price target on shares of Johnson & Johnson from $168.00 to $167.00 and set an “equal weight” rating on the stock in a report on Wednesday, April 17th. HSBC upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating and lifted their price target for the company from $169.00 to $170.00 in a report on Thursday, April 18th. Finally, Royal Bank of Canada reiterated an “outperform” rating and issued a $175.00 price target on shares of Johnson & Johnson in a report on Monday, June 17th. Eight research analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $174.07.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.